Aumolertinib challenge as an optional treatment in advanced non small‑cell lung cancer after osimertinib failure with epidermal growth factor receptor‑sensitive mutation: A case series

Abstract

Osimertinib, as the first third‑generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), has been recommended universally as the priority front‑line therapeutic for advanced non‑small cell lung cancer (NSCLC) carrying EGFR‑sensitive mutations. However, patients inevitably acquire drug resistance to osimertinib. Aumolertinib is the second third‑generation EGFR‑TKI and has been similarly approved as a first‑line treatment agent. The present study reports the cases of 3 patients who were challenged with aumolertinib after osimertinib failure. All 3 patients achieved a partial remis‑ sion. The progression‑free survival periods following aumolertinib were 10.0, 11 and 9.0 months (at the time of writing the study). Although the patient in case 2 succumbed to an intracerebral hemorrhage due to hypertension, aumoler‑ tinib remained effective as a treatment in cases 1 and 3. The present case series suggests the use of aumolertinib chal‑ lenge as an optional treatment for patients with metastatic NSCLC harboring EGFR‑sensitive mutations after osimer‑ tinib failure. The therapeutic strategy of switching from osimertinib to aumolertinib is worth exploring further in the near future.